Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Iterative Screening

Sygnature’s experience together with our open and transparent communication, enhanced by the co-location of our scientific teams, ensures efficient, cost-effective and optimised Design-Make-Test-Analyse cycles to expedite the progression of your project through the discovery pipeline.

Our state of the art automated liquid-handling capabilities enables rapid and robust turnaround of routine screening data, with either ‘spot’ tests at a single concentration or full concentration-response curves being generated for each test compound. Together with Sygnature’s comprehensive Informatics System, our automation platform and the experience of the scientific teams, enables accelerated design-make-test-analyse (DMTA) cycles, to rapidly identify Structure-Activity Relationships (SAR) to enable efficient compound optimisation and clinical candidate nomination.

Result: Clinical candidate nomination with the desired property profile for the target of interest.

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.